To describe the relief of symptoms, tolerability, and compliance of treatment with Klacid® sustained release (SR) at a dose of 1000 mg once daily in patients with acute tracheitis, acute tracheobronchitis, acute bronchitis, or in patients with acute exacerbation of chronic bronchitis or mild community-acquired pneumonia. This postmarketing observational study is non-interventional and is being conducted in a prospective, single-arm, single-country, multicenter format. Klacid SR will be prescribed in usual manner in accordance with the terms of the local market authorization with regards to dose, population, and indication as well as with local guidelines.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Body Temperature
Timeframe: Visit 1 (initial visit), Visit 2 (10th-16th day or any other day after Visit 1 defined by physician)
Cough and Its Character
Timeframe: Visit 1 (initial visit), Visit 2 (10th-16th day or any other day after Visit 1 defined by physician)
Dyspnoea
Timeframe: Visit 1 (initial visit), Visit 2 (10th-16th day or any other day after Visit 1 defined by physician)
Auscultation Findings
Timeframe: Visit 1 (initial visit), Visit 2 (10th-16th day or any other day after Visit 1 defined by physician)
Chest Xray - Necessary for Verification of the Diagnosis of Pneumonia , Community-acquired Pneumonia
Timeframe: Visit 1 (Initial visit)
Previous Prescription of Other Antibiotic (Answer Whether Klacid SR is Given as the First or as Second Antibiotic)
Timeframe: Visit 1 (Initial visit)
Therapeutic Response
Timeframe: Visit 2 (10th-16th day or any other day after Visit 1 defined by physician)